Akero Therapeutics, Inc. (NASDAQ:AKRO) VP Sells $12,882.16 in Stock

Akero Therapeutics, Inc. (NASDAQ:AKRO) VP Patrick Lamy sold 569 shares of the company’s stock in a transaction dated Tuesday, June 11th. The shares were sold at an average price of $22.64, for a total transaction of $12,882.16. Following the transaction, the vice president now directly owns 18,562 shares of the company’s stock, valued at $420,243.68. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Akero Therapeutics Trading Down 2.6 %

Shares of NASDAQ AKRO opened at $23.98 on Friday. Akero Therapeutics, Inc. has a 1 year low of $11.25 and a 1 year high of $56.66. The company has a debt-to-equity ratio of 0.04, a current ratio of 30.12 and a quick ratio of 30.12. The firm has a 50-day moving average of $20.83 and a 200 day moving average of $22.35. The stock has a market cap of $1.66 billion, a P/E ratio of -7.49 and a beta of -0.31.

Akero Therapeutics (NASDAQ:AKRO) last released its earnings results on Friday, May 10th. The company reported ($0.90) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.90). As a group, sell-side analysts expect that Akero Therapeutics, Inc. will post -3.82 EPS for the current fiscal year.

Analyst Ratings Changes

A number of research analysts have commented on the company. UBS Group upped their price target on Akero Therapeutics from $39.00 to $42.00 and gave the company a “buy” rating in a research report on Tuesday, March 5th. Cantor Fitzgerald restated an “overweight” rating on shares of Akero Therapeutics in a report on Wednesday. Evercore ISI cut their price target on shares of Akero Therapeutics from $50.00 to $38.00 and set an “outperform” rating on the stock in a report on Wednesday, May 15th. HC Wainwright reaffirmed a “buy” rating and set a $50.00 target price on shares of Akero Therapeutics in a research note on Tuesday, June 11th. Finally, Canaccord Genuity Group lowered their price objective on shares of Akero Therapeutics from $59.00 to $56.00 and set a “buy” rating for the company in a report on Monday, May 13th. One investment analyst has rated the stock with a hold rating and eight have given a buy rating to the company. According to MarketBeat, Akero Therapeutics has an average rating of “Moderate Buy” and an average price target of $41.13.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the stock. Headlands Technologies LLC purchased a new stake in shares of Akero Therapeutics in the fourth quarter worth $28,000. Russell Investments Group Ltd. boosted its stake in Akero Therapeutics by 2,366.0% in the 1st quarter. Russell Investments Group Ltd. now owns 1,233 shares of the company’s stock worth $31,000 after purchasing an additional 1,183 shares in the last quarter. Quarry LP grew its position in Akero Therapeutics by 40.0% during the 4th quarter. Quarry LP now owns 1,750 shares of the company’s stock valued at $41,000 after purchasing an additional 500 shares during the last quarter. Strs Ohio increased its stake in Akero Therapeutics by 100.0% during the 4th quarter. Strs Ohio now owns 2,000 shares of the company’s stock valued at $46,000 after purchasing an additional 1,000 shares in the last quarter. Finally, Orion Capital Management LLC purchased a new position in Akero Therapeutics in the third quarter worth about $51,000.

About Akero Therapeutics

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.